All Outputs (4)

Investigating the role of CBX2 in ER- positive breast cancer (2019)
Thesis
Waters, E. J. (2019). Investigating the role of CBX2 in ER- positive breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4222704

Breast cancer is the most common form of cancer in women, with oestrogen receptor (ER) positive breast cancers being the most common subtype. Although there are targeted endocrine therapies for this receptor, resistance mechanisms mean that they are... Read More about Investigating the role of CBX2 in ER- positive breast cancer.

Investigating the role of CBX2 in models of triple negative breast cancer (2019)
Thesis
Warren, C. (2019). Investigating the role of CBX2 in models of triple negative breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4222872

Breast cancer accounts for around 11,500 deaths per year in the UK in women. There are several subtypes of breast cancer including triple negative breast cancer (TNBC) which is categorised by a lack of oestrogen, progesterone and human epidermal grow... Read More about Investigating the role of CBX2 in models of triple negative breast cancer.

The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer (2019)
Journal Article
Jones, D., Wilson, L., Thomas, H., Gaughan, L., & Wade, M. A. (2019). The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer. Cancers, 11(8), Article 1122. https://doi.org/10.3390/cancers11081122

Many estrogen receptor (ER)-positive breast cancers develop resistance to endocrine therapy but retain canonical receptor signalling in the presence of selective ER antagonists. Numerous co-regulatory proteins, including enzymes that modulate the chr... Read More about The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer.

The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart (2019)
Journal Article
Onwuli, D. O., Samuel, S., Sfyri, P., Welham, K., Goddard, M., Abu-Omar, Y., Loubani, M., Rivero, F., Matsakas, A., Benoit, D. M., Wade, M., Greenman, J., & Beltran-Alvarez, P. (2019). The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart. International journal of cardiology, 282, 76-80. https://doi.org/10.1016/j.ijcard.2019.01.102

Background
The inhibitory subunit of cardiac troponin (cTnI) is a gold standard cardiac biomarker and also an essential protein in cardiomyocyte excitation-contraction coupling. The interactions of cTnI with other proteins are fine-tuned by post-tra... Read More about The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart.